Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. September 2018 05:30 ET | Quelle: Opthea Limited

Opthea to Host Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum in New York City

MELBOURNE, Australia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to announce that it will host...
14. September 2018 05:30 ET | Quelle: Opthea Limited

Opthea Presents Phase 1/2a Data of OPT-302 in wet AMD at the Retina Society 2018 Annual Meeting

MELBOURNE, Australia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage clinical biopharmaceutical company developing first-in-class novel biologic therapies to treat...
05. September 2018 05:30 ET | Quelle: Opthea Limited

Opthea Receives Positive Interim Review from Independent Safety Committee in Phase 2b Wet AMD Clinical Trial

MELBOURNE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, today...
30. Juli 2018 06:00 ET | Quelle: Opthea Limited

Opthea Doses First Patient in Phase 2a Trial for OPT-302 in Diabetic Macular Edema

MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, has...
26. Juli 2018 05:30 ET | Quelle: Opthea Limited

Opthea Meets Primary Safety Objective with OPT-302 in Phase 1b Diabetic Macular Edema Clinical Trial

MELBOURNE, Australia, July 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases,...
02. Juli 2018 05:30 ET | Quelle: Opthea Limited

Opthea’s Phase 2b Wet AMD Clinical Trial Reaches Mid-Way Point of Patient Recruitment

MELBOURNE, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, is...
27. März 2018 05:30 ET | Quelle: Opthea Limited

Opthea Doses Patients in Europe and Israel in Phase 2b Study of OPT-302 for Wet AMD

MELBOURNE, Australia, March 27, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, has dosed the first patients in Europe...
03. Januar 2018 05:30 ET | Quelle: Opthea Limited

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

MELBOURNE, Australia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, has...
19. Dezember 2017 05:30 ET | Quelle: Opthea Limited

Opthea Doses First Patient in Phase 2b Study of OPT-302 for Wet AMD

MELBOURNE, Australia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, announced today the dosing of the first...